The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
HH - just to remind you what you posted less than 24 hours ago. You just can't seem to help yourself. Put the twat in the bin and never take him out. Anyone else replying to him - the same advice.
"Ignore Stu19 Feb 2024 22:36
Would suggest the board ignores Stu. He has previous here - he is only here because he is short and panicking. He goes quiet when things going his way and reruns here when things are not."
Try telling that to a number of my front line colleagues who sadly passed away during the early stages of the pandemic. No underlying conditions and as young as 26 years old. No issue in you not getting jabbed but maybe if you’d lost your nearest and dearest, you may have a different opinion.
Haywain - in regards to this sentence “ I particularly like the idea of conjugating the CBR mRNA with an aptamer for targeted delivery” - could it also be conjugated to Avacta’s Affimer technology ? I believe that Affimers have more advantages to aptamers.
I have been here years Jinx - 1st buy was in July 2020. I don’t disagree that he is lacking as a CEO but whoever made the 1p placing comment really doesn’t know what they’re talking about. He’s told us countless times that his Twitter account is not linked to the business but then posts some cryptic Tweets - he doesn’t do himself any favours on that front.
I still don’t get why you think going to 1p would be of benefit to the Sandlers so please explain your logic.
Rory - have you emailed your concerns to AS or the company ? Maybe doing so will force them to think of an alternative solution. Maybe use Myles' questions but instead of it being an in person interview, the answers could be posted on the Avacta website for all to read at the same time. It doesn't need to be an RNS.
Moorscloud - not sure about this "RegV - it has been convincingly explained many times that Vlad's plan has always been to licence / sell CAR-T in order to move forward with CDX and CBR."
You've based this purely on comments on this board, which, at best are a guess. Nowhere have I seen in an RNS that this is the plan. Please could you point me to any communication from the company which supports your statement. Please do not make statements of fact without being able to back them up.